Reactive Biosciences

Reactive Biosciences is a private, pre-clinical stage biotech leveraging a proprietary boron-based drug discovery platform to target previously inaccessible disease biology. The company is assembling a seasoned leadership team with strong scientific founders and is actively seeking partnerships to accelerate its platform and pipeline. While still early-stage, its approach aims to unlock novel therapeutic mechanisms in high-need areas where traditional small molecules have failed.

Proprietary boron-based drug discovery platform utilizing boron's unique chemistry to access novel binding sites and target historically undruggable biology.

Reactive competes in the broad field of novel therapeutic modality discovery, including companies focused on covalent inhibitors, proteolysis-targeting chimeras (PROTACs), molecular glues, and other approaches to difficult targets. Its specific focus on boron chemistry places it in a niche with a small but growing number of specialized biotechs and academic groups.